- Accesswire•5 hours agoIMPORTANT INVESTOR ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm
IRVINE, CA / ACCESSWIRE / February 24, 2017 / Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Regulus Therapeutics Inc. ("Regulus" or the "Company") ...
- Accesswire•6 hours agoSHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regulus Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline - RGLS
NEW YORK, NY / ACCESSWIRE / February 24, 2017 / Pomerantz LLP announces that a class action lawsuit has been filed against Regulus Therapeutics Inc. ("Regulus" or the "Company") (NASDAQ: ...
- PR Newswire•yesterday
Regulus will host a conference call and webcast on March 2, 2017 at 5:00 p.m. Eastern Time to discuss fourth quarter and full year 2016 financial results and provide a general business update. A live webcast of the call will be available online at www.regulusrx.com. To access the call, please dial (877) 257-8599 (domestic) or (970) 315-0459 (international) and refer to conference ID 75961316. Regulus Therapeutics Inc. (RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus has leveraged its oligonucleotide drug discovery and development expertise to develop a well-balanced microRNA therapeutics pipeline complemented by a rich intellectual property estate to retain its leadership in the microRNA field. Regulus is advancing several programs in renal, hepatic and central nervous systems diseases, both independently and with our strategic alliance partners, Sanofi and AstraZeneca.
RGLS : Summary for Regulus Therapeutics Inc. - Yahoo Finance
Regulus Therapeutics Inc. (RGLS)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
|Bid||1.00 x 3000|
|Ask||1.35 x 600|
|Day's Range||0.94 - 1.10|
|52 Week Range||0.94 - 8.90|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-0.84|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|